Clin2
NCT07344051Likely a fitNot yet recruiting

A trial of QLS12010 for moderate to severe eczema

Moderate-to-severe Atopic Dermatitis

Treatments studied

Part of Immune system & allergy, Skin clinical trials.

This trial tests an experimental oral medication, QLS12010, for adults with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and itching.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
160 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have had eczema for at least 1 year
  • Your eczema covers at least 10% of your body
  • You have a moderate to severe case as rated by the doctor
  • You have had an average itch score of at least 4 out of 10 in the week before starting the trial
  • You have not used any other experimental drugs in the last 3 months
  • You are not pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07465120Not yet recruiting· Phase 2
Testing CMS-D001 for moderate to severe eczema

This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.

Beijing, Beijing Municipality
NCT07370909Recruiting· Phase 3
Oral LW402 for moderate-to-severe eczema

This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.

Beijing
NCT06723080Recruiting· Phase 3
Oral VC005 for moderate to severe eczema

This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.

Nanjing, Jiangsu
NCT06946641Recruiting· Phase 1
Testing QLS12010 safety in healthy adults and people with eczema

This trial tests a new drug, QLS12010, to see if it is safe and how it works in healthy volunteers and in people with moderate to severe atopic dermatitis (eczema). It may offer a new treatment option for those whose eczema has not improved with topical creams.

Beijing
NCT06880276Recruiting· Phase 3
Studying QLM3003 ointment for mild or moderate eczema

This trial tests if an ointment called QLM3003 is safe and helps adults with mild to moderate atopic dermatitis (eczema). It may be a new treatment option for people whose eczema affects small areas of skin.

Shenyang
NCT07235384Recruiting· Phase 1
Zai Lab tests ZL-1503 for moderate to severe eczema

This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.

Woolloongabba, Queensland

Hear when a new Moderate to Severe Atopic Dermatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.